ABSTRACT:
Background: The goal of this study was to fabricate SLNs loaded with dasatinib and hesperidin for the treatment of chronic myeloid leukemia (CML). Materials and Methods: The "central composite design (CCD)" was employed to improve the dasatinib/hesperidin loaded-SLNs during synthesis using a high-shear homogenizer. Results: Particle diameter index (PDI), average entrapment efficiency (AE), and particle size (nm) were all 0.12% for the improved SLNs. Hence, the polydispersity was enhanced by increasing both the total amount of Compritol and the sonication period. With poloxamer 188 content, the polydispersity index was significantly reduced, and the SLN's entrapment efficiency (EE) was determined to be 90%. The SLNs' anticancer activity was tested in-vitro and in-vitro cell viability tests (MTT), and their TEM, SEM, FTIR, DSC, and HPLC analysis was done. Dasatinib and hesperidin-containing 200-nm SLNs are spherical and rounded. The pharmaceuticals and excipients were shown to be compatible using DSC and FTIR analyses. For 48 hours, the drug release from the improved SLN formulation was monitored. Results showed that the medicine had a slow but steady release of its active ingredients; the first four hours saw the release of 28% of the drug, while the next two days saw the release of 75%. Conclusion: This study developed and tested SLNs loaded with dasatinib and hesperidin, an innovative formulation method that does not include harmful excipients. The aim was to treat chronic myeloid leukemia (CML).
Cite this article:
Moinuddin, Pavan Kumar. Formulation and in Vitro Evaluation of Dasatinib and Hesperidin-Loaded Lipid Nanoformulation for Anticancer Therapy. Research Journal of Pharmacy and Technology. 2026;19(1):119-5. doi: 10.52711/0974-360X.2026.00018
Cite(Electronic):
Moinuddin, Pavan Kumar. Formulation and in Vitro Evaluation of Dasatinib and Hesperidin-Loaded Lipid Nanoformulation for Anticancer Therapy. Research Journal of Pharmacy and Technology. 2026;19(1):119-5. doi: 10.52711/0974-360X.2026.00018 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2026-19-1-18
REFERENCES:
1. Lian W, Wong J, Tan EJ, Foo LL, Ong KH, Htun HL. Classic myeloproliferative neoplasms in Singapore: 1968–2017 population-based incidence, trends, and survival. Cancer Epidemiology. 79: 102175, 2022. The DOI is 10.1016/j.canep.2022.102175.
2. Katogiannis K, Ikonomidis I, Panou F, Katsimardos A, Divane A, Tsantes A, et al. (2023) Cardiopulmonary arrest from leukostasis in early chronic myeloid leukemia. Journal of Medical Cases. 2018; 9(3): 77–82. The DOI is 10.14740/jmc2993w.
3. Diagnosis, Treatment, and Monitoring of Chronic Myeloid Leukemia: 2018 Update. American Journal of Hematology. 2018; 93(3): 442–459. Available at: 10.1002/ajh.25011.
4. Jabbour, E., and Kantarjian, H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy, and surveillance. American Journal of Hematology. 2020; 95(6): 691–709. Available at: DOI: https://doi.org/10.1002/ajh.25792
5. Vanneman, M., and Dranoff, G. Combining immunotherapy with targeted therapies in cancer treatment. Nature Reviews Cancer. 2012; 12 (4): 237–251.
6. Smyth, L.A., and Collins, I. Evaluating and clarifying the selectivity of protein kinase inhibitors. Journal of Chemical Biology. 2009; 2(3): 131–151.
7. Hu J., Xing K., Zhang Y., Liu M., Wang Z. 7. Global Research Trends in Tyrosine Kinase Inhibitors: Co-word and Visualization Analysis. JMIR Medical Informatics. 2022; 10(4): 1–18.
8. Lopina N., Dmytrenko I., Hamov D., Lopin D., Dyagil I. A Novel Framework for Cardio-Hematological Monitoring in Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitors. Cureus. 2022; 14(6): 5–14. Available at: DOI: https://doi.org/10.7759/cureus.25766
9. Jim HSL, Hyland KA, Nelson AM, Pinilla-Ibarz J, Sweet K, Gielissen M, et al. Web-based cognitive behavioral intervention for therapy-related fatigue in chronic myeloid leukemia: Results from a pilot randomized research. Cancer. 2020; 126(1): 174–180. Accessible at: DOI: https://doi.org/10.1002/cncr.32521
10. Saleh N,Allam T, Korany RMS, Abdelfattah AM, Omran AM, Abd Eldaim MA, et al. Protective and Therapeutic Efficacy of Hesperidin versus Cisplatin against Ehrlich Ascites Carcinoma-Induced Renal Damage in Mice. Pharmaceuticals. 2022; 15(3): 294. Available from: DOI: https://doi.org/10.3390/ ph15030294
11. Sulaiman GM, Waheeb HM, Jabir MS, Khazaal SH, Dewir YH, Naidoo Y. Hesperidin Loaded on Gold Nanoparticles as a Drug Delivery System for a Successful Biocompatible, Anti-Cancer, Anti-Inflammatory and Phagocytosis Inducer Model. Sci Rep. 2020; 10(1): 1–16.Available from: DOI:https://doi.org/10.1038/ s41598-020-66419-6
12. Bhattacharya, T., Soares, G. ABE., Chopra, H., et al. Application of Phyto-Nanotechnology in the Treatment of Neurodegenerative Disorders. Materials (Basel). 2022; 15(3) 804. Available through DOI: https://doi.org/10.3390/ma15030804
13. Yang, S.X., and Dancey, J.E. Handbook of Therapeutic Biomarkers in Cancer, 2nd Edition. Jenny, Stanford Publishing. New York: 2021. Available at: DOI: https://doi.org/10.1201/9781003159469
14. Wolfe HR, Rein LAM. The Evolving Dynamics of Frontline Therapy in Chronic Phase Chronic Myeloid Leukemia (CML). Current Hematology and Malignancy Reports. 2021; 16: 448–454. Available through DOI: https://doi.org/10.1007/s11899-021-00655-z
15. He S, Bian J, Shao Q, Zhang Y, Hao X, Luo X, et al. Therapeutic Drug Monitoring and Personalized Medicine of Dasatinib: Focus on Clinical Pharmacokinetics and Pharmacodynamics. Frontiers in Pharmacology. 2021; 12: 1–11. Available at: DOI: https://doi.org/10.3389/fphar.2021.797881
16. Katogiannis K, Ikonomidis I, Panou F, Katsimardos A, Divane A, Tsantes A, et al. Cardiopulmonary arrest from leukostasis in early chronic myeloid leukemia. Journal of Medical Cases. 2018; 9(3): 77–82. The DOI is 10.14740/jmc2993w.
17. Emad NA, Ahmed B, Alhalmi A, Alzobaidi N, Al-Kubati SS. Recent progress in nanocarriers for direct nose to brain drug delivery. J Drug Deliv Sci Technol. 2021; 64: 102642. Available from: DOI: https://doi.org/10.1016/J.JDDST.2021.102642.
18. Alhalmi A, Amin S, Beg S, Al-Salahi R, Mir SR, Kohli K. Formulation and optimization of naringin loaded nanostructured lipid carriers using Box-Behnken based design: Invitro and ex vivo evaluation. J Drug Deliv Sci Technol. 2022; 74(June): 103590. Available from: DOI: https://doi. org/10.3390/pharmaceutics14091771
19. Aggarwal V, Tuli HS, Thakral F, Singhal P, Aggarwal D, Srivastava S, et al. Molecular mechanisms of action of hesperidin in cancer: Recent trends and advancements. Exp Biol Med. 2020; 245(5): 486–97. Available from: DOI:https://doi. org/10.1177/1535370220903671
20. Saleh N, Allam T, Korany RMS, Abdelfattah AM,Omran AM, Abd Eldaim MA, et al. Protective and Therapeutic Efficacy of Hesperidin versus Cisplatin against Ehrlich Ascites Carcinoma-Induced Renal Damage in Mice. Pharmaceuticals. 2022; 15(3): 294. Available from: DOI: https://doi.org/10.3390/ ph15030294
21. Sulaiman GM, Waheeb HM, Jabir MS, Khazaal SH, Dewir YH, Naidoo Y. Hesperidin Loaded on Gold Nanoparticles as a Drug Delivery System for a Successful Biocompatible, Anti-Cancer, Anti-Inflammatory and Phagocytosis Inducer Model. Sci Rep. 2020; 10(1): 1–16. Availablefrom: DOI:https://doi.org/10.1038/ s41598-020-66419-6
22. Martins S, Sarmento B, Ferreira DC, Souto EB. Lipid-based colloidal carriers for peptide and protein delivery - Liposomes versus lipid nanoparticles. Int J Nanomedicine. 2007; 2(4): 595– 607. Available from:https://pubmed.ncbi.nlm.nih.gov/18203427/
23. Russo E, Spallarossa A, Tasso B, Villa C, Brullo C. Nanotechnologyoftyrosinekinaseinhibitorsincancertherapy: Aperspective. Int J Mol Sci. 2021; 22(12): 6538. Available from: DOI: https://doi.org/10.3390/ijms22126538
24. Emad NA, Ahmed B, Alhalmi A, Alzobaidi N, Al-Kubati SS. Recent progress in nanocarriers for direct nose to brain drug delivery. J Drug Deliv Sci Technol. 2021; 64: 102642. Available from: DOI: https://doi.org/10.1016/J.JDDST.2021.102642
25. Rasoulian F, Eskandani M, Akbari Nakhjavani S, Eskandani M. Acriflavine-loaded solid lipid nanoparticles: preparation, physicochemical characterization, and anti-proliferative properties. Pharm Dev Technol. 2021; 26(9): 934–42. Available from: DOI: https://doi.org/10.1080/10837450.2021.1 963276
26. Gupta MK, Swarnkar SK. Preformulation Studies of Diltiazem Hydrochloride from Tableted Microspheres. J Drug Deliv Ther. 2018; 8(1): 64–9. Available from: DOI:https://doi.org/10.22270/ jddt.v8i1.1552
27. Khunteta A, Gupta MK, Swarnkar SK. Formulation of Rapid Dissolving Films Containing Granisetron Hydrochloride and Ondansetron Hydrochloride. J Drug Deliv Ther. 2019; 9(4-A): 516–27. Available from: DOI:https://doi.org/10.22270/jddt. v9i4-A.3525
28. Mudgil M, Gupta N, Nagpal M, Pawar P. Nanotechnology: A new approach for ocular drug delivery system. International Journal of Pharmacy and Pharmaceutical Sciences. 2012; 4(2): 105-12.
29. Jain S, Jain S, Khare P, Gulbake A, Bansal D, Jain SK. Design and development of solid lipid nanoparticles for topical delivery of an anti-fungal agent. Drug Deliv. 2010; 17(6): 443–51. Available from: DOI: https://doi.org/10.3109/10717544.2010.483252
30. Khunteta A, Gupta MK, Swarnkar SK. Formulation of Rapid Dissolving Films Containing Granisetron Hydrochloride and Ondansetron Hydrochloride. J Drug Deliv Ther. 2019; 9(4- A): 516–27. Available from:DOI:https://doi.org/10.22270/jddt. v9i4-